Immune checkpoint inhibitors plus VEGF tyrosine kinase inhibitors as second-line or later therapy for patients with extensive stage small cell lung cancer

被引：0
作者：
Yan, N. [1 ]
Guo, S. X. [1 ]
Li, M. J. [1 ]
Huang, S. Y. [1 ]
Guo, Q. Q. [1 ]
Geng, D. [1 ]
Zhang, H. X. [1 ]
Li, X. [2 ]
机构：
[1] Zhengzhou Sch Med, Affiliate Hosp 1, Oncol Dept, Zhengzhou, Peoples R China
[2] Zhengzhou Univ, Affiliated Hosp 1, Med Oncol, Zhengzhou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.243
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1659P
引用
收藏
页码：S1168 / S1168
页数：1
相关论文
共 50 条
  • [1] Immune checkpoint inhibitors in extensive-stage small cell lung cancer
    Zhang, Tongmei
    JOURNAL OF THE NATIONAL CANCER CENTER, 2022, 2 (03): : 130 - 131
  • [2] Efficacy and safety analysis of anlotinib in combination with immune checkpoint inhibitors for second-line and subsequent extensive-stage small-cell lung cancer
    Ying, Xixi
    Shi, Zheng
    Shao, Rongjun
    You, Guangxian
    Song, Zhengbo
    NEOPLASMA, 2024, 71 (03) : 297 - 305
  • [3] Immune checkpoint inhibitors are superior to docetaxel as second-line therapy for patients with non-small cell lung carcinoma
    Fillon, Mike
    CA-A CANCER JOURNAL FOR CLINICIANS, 2018, 68 (03) : 178 - 179
  • [4] Second-line treatment of non-small-cell lung cancer: chemotherapy or tyrosine kinase inhibitors?
    Passaro, Antonio
    Cortesi, Enrico
    de Marinis, Filippo
    EXPERT REVIEW OF ANTICANCER THERAPY, 2011, 11 (10) : 1587 - 1597
  • [5] FDA analysis of immune checkpoint inhibitors in combination with vascular endothelial growth factor tyrosine kinase inhibitors in the second-line treatment of patients with advanced non-small cell lung cancer
    Malinou, Justin Nathaniel
    Mehta, Gautam
    Vellanki, Paz J.
    Larkins, Erin A.
    Kluetz, Paul Gustav
    Singh, Harpreet
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] Immune checkpoint inhibitors: a new landscape for extensive stage small cell lung cancer treatment
    Bianco, Andrea
    D'Agnano, Vito
    Matera, Maria Gabriella
    Della Gravara, Luigi
    Perrotta, Fabio
    Rocco, Danilo
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2021, 15 (11) : 1415 - 1425
  • [7] Immune-checkpoint inhibitors plus chemotherapy versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer
    Zhou, Fei
    Zhao, Wencheng
    Gong, Xiaomei
    Ren, Shengxiang
    Su, Chunxia
    Jiang, Tao
    Zhou, Caicun
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
  • [8] Second-line therapy in advanced non-small cell lung cancer: Cytotoxic agents or tyrosine kinase inhibitors? Our experience
    Caristi, N.
    Franchina, T.
    Proto, C.
    Chiofalo, G.
    Toscano, G.
    Scimone, A.
    Zanghi, M.
    Berenato, R.
    Briguglio, R.
    Denaro, N.
    Noto, L.
    Adamo, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [9] Obesity, Sarcopenia, and Outcomes in Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors
    Khaddour, Karam
    Gomez-Perez, Sandra L.
    Jain, Nikita
    Patel, Jyoti D.
    Boumber, Yanis
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [10] Anaplastic lymphoma kinase (ALK) inhibitors for second-line therapy of non-small cell lung cancer
    Berghmans, Thierry
    Remmelink, Myriam
    Awada, Ahmad
    LUNG CANCER-TARGETS AND THERAPY, 2012, 3 : 91 - 99
12345